Survival effects of ZDV, ddI, and ddC on patients with CD4 <= 50 cells/mm3

Article Abstract:

There seems to be no evidence to suggest that drug treatment effects are lower in patients with advanced as compared to less advanced stages of human immunodeficiency virus (HIV) disease. CD4 cell counts less than 50 indicate advanced HIV disease. Researchers analyzed and pooled the data from 7 studies that tested the effectiveness of the drugs zidovudine, dideoxyinosine, and dideoxycytosine on 3,882 patients with HIV. They compared the data on patients with CD4 counts of less than and more than 50. Overall, more patients with CD4 counts less than 50 died than those with CD4 counts more than 50 for all treatments studied. However, the number of deaths are similar across CD4 cell count lines within each study.

Physiological aspects, CD4 lymphocytes, Zalcitabine

---

A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease

Article Abstract:

Triple combination therapy with nevirapine, zidovudine and didanosine appears to be effective even in patients with advanced HIV infection. Nevirapine belongs to a class of drugs called nonnucleoside reverse transcriptase inhibitors. Researchers randomly assigned 68 patients with advanced HIV infection to take nevirapine, zidovudine and didanosine or zidovudine and didanosine. None of the patients had received AIDS drugs in the past. Those receiving triple therapy had greater reductions in viral levels and greater increases in CD4 T cell counts comparing to those taking two drugs.

---

Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression

Article Abstract:

Patients taking zidovudine whose HIV infection continues to progress may do better by switching to didanosine. Of 400 AIDS patients who continued to decline on zidovudine, 133 continued on zidovudine, 136 began low-dose didanosine and 131 began high-dose didanosine. Didanosine reduced the frequency of AIDS-related illnesses, especially in those with higher CD4 counts. Patients taking didanosine were more likely to experience increases in CD4 cell counts. However, mortality rates were similar in all three groups.

Similar abstracts:

• Abstracts: Improving practice in wound care for patients with dementia
• Abstracts: Fetal fibronectin levels are elevated in maternal plasma and amniotic fluid of patients with severe preeclampsia
• Abstracts: Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis. Cytokine production by endothelial cells infected with human T cell lymphotropic virus type I
• Abstracts: Panel at work on patient bill of rights. Quality data target providers, payers
• Abstracts: Coal worker's pneumoconiosis: CT assessment in exposed workers and correlation with radiographic findings. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.